# Fredun Pharmace (NSE: FREDUN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FREDUN · Pivot · prices to 21 Oct 2026

Fredun Pharmace (NSE: FREDUN) closed at ₹1,392.00 on 21 Oct 2026. With a market capitalisation of ₹2,373 Cr, it ranks 1089th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 23.4× trailing earnings, against a return on equity of 14.7% in FY25. Its 52-week range is ₹1,195.20 (16 Sep 2026) to ₹1,665.00 (8 Oct 2026); the last close is 16.4% below the high. Promoters held 44.57% of the company as of 16 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,392.00 |
| Market cap | ₹2,373 Cr |
| P/E (trailing) | 23.4 |
| ROE | 14.7% (FY25) |
| ROCE | 31.8% (FY25) |
| Debt to equity | 1.18 |
| 52-week high | ₹1,665.00 (8 Oct 2026) |
| 52-week low | ₹1,195.20 (16 Sep 2026) |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹454 Cr | ₹21 Cr |
| FY24 | ₹348 Cr | ₹16 Cr |
| FY23 | ₹275 Cr | ₹11 Cr |
| FY22 | ₹224 Cr | ₹6 Cr |
| FY21 | ₹134 Cr | ₹2 Cr |
| FY20 | ₹113 Cr | ₹2 Cr |

## Shareholding (16 Jul 2026)

- Promoters: 44.57%
- Foreign institutions: 1.06%
- Domestic institutions: 2.94%
- Non-institutions: 51.43%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,083.50 | ₹2,457 Cr | — | — |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹95.20 | ₹2,445 Cr | 7.7 | — |
| [Venus Remedies](https://app.pivotnow.in/stock/VENUSREM) | ₹1,796.10 | ₹2,401 Cr | 23.3 | — |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹146.03 | ₹2,290 Cr | 23.5 | — |
| [Vimta Labs](https://app.pivotnow.in/stock/VIMTALABS) | ₹505.00 | ₹2,256 Cr | 29 | — |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹297.65 | ₹2,224 Cr | 24.5 | — |

## Questions and answers

### What is the share price of Fredun Pharmace today?

Fredun Pharmace (NSE: FREDUN) last closed at ₹1,392.00 on 21 Oct 2026. Its 52-week high is ₹1,665.00 and its 52-week low is ₹1,195.20.

### What is the market cap of Fredun Pharmace?

Fredun Pharmace's market capitalisation is ₹2,373 Cr (₹2,373 Cr) at the 19 Oct 2026 close, ranking 1089th among the NSE companies Pivot tracks.

### What is the P/E ratio of Fredun Pharmace?

Fredun Pharmace trades at a trailing P/E of 23.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 23.5.

### What is the ROE and ROCE of Fredun Pharmace?

Return on equity was 14.7% in FY25 and return on capital employed was 31.8% in FY25 (standalone figures).

### Is Fredun Pharmace a debt-free company?

No. Fredun Pharmace's debt-to-equity ratio was 1.18 in FY25, with total debt of ₹10 Cr.

### What is the shareholding pattern of Fredun Pharmace?

As of 16 Jul 2026: promoters 44.57%, foreign institutions 1.06%, domestic institutions 2.94%, non-institutions 51.43%.

### Who are Fredun Pharmace's competitors?

The listed Pharma & Healthcare companies closest to Fredun Pharmace by market cap are Dr Agarwals Eye Hospital, Alembic, Venus Remedies, Dishman Carbogen Amcis, Vimta Labs and Medi Assist Healthcare Services.

### Is Fredun Pharmace a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fredun Pharmace's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FREDUN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.